Synergy Pharmaceuticals (Ticker: SGYP)


Company: Synergy Pharmaceuticals
Ticker Symbol: SGYP
Action: SELL

1/2/13 Update… Just wanted to give you a heads up. Synergy Pharm (SGYP) has been trading up 18-20% in pre-market trading. Looks like they got some positive results!

I’m glad we stuck around as the last two days have been great! Right now it looks like it is set to open around $6.20. I got in around $5.15 so that’s a quick 20% advance. I will check out the options activity when
the markets open and most likely will put in a sell today to lock in that gain.

12/22/12 Update… SGYP was down  9 cents for the week or -1.77% for the week.  This one still has quite a bit of upside potential.  This article is a must read:

12/15/12 Update:  This stock was our one blemish last week. The other three stocks and Infinity (INFI), which was sold on good news were all up double digits.  SGYP was down 1.6% for the week. Synergy’s leading compound plecanatide has been showing promise in treating patients with idiopathic constipation and constipation predominant irritable bowel syndrome.  This stock has a catalyst ahead with a key data release on lead product candidate Plecanatide in the near future.  Insiders are bullish on this one as well.

12/12/12 Update:  Bought in @ $5.15. Stop loss in at $4.25

12/11/12 Our Analysis: Synergy Pharmaceuticals (SGYP)is a Renegade stock with great upside potential. It a bigger winner for November (+40%). The real catalyst event is weeks away with the expectations of a Plecanatide Phase IIb/III results release, and it’s possible that shares could quickly take off. If it reports positive results, then this stock could hit $8-$10. This will be a volatile stock and not for the faint of heart. I am looking to get in under $5.25.

Synergy (SGYP) is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy’s lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal [GI] hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation [CIC] patients. In October, 2011, Synergy initiated dosing of patients in a major Phase IIb/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy’s second GC-C agonist SP-333 is in clinical development to treat inflammatory bowel diseases, and is presently in a Phase I trial in healthy volunteers.